CA2007641A1 - Combination of squalene synthetase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination - Google Patents
Combination of squalene synthetase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combinationInfo
- Publication number
- CA2007641A1 CA2007641A1 CA002007641A CA2007641A CA2007641A1 CA 2007641 A1 CA2007641 A1 CA 2007641A1 CA 002007641 A CA002007641 A CA 002007641A CA 2007641 A CA2007641 A CA 2007641A CA 2007641 A1 CA2007641 A1 CA 2007641A1
- Authority
- CA
- Canada
- Prior art keywords
- combination
- pharmaceutical
- squalene synthetase
- serum cholesterol
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 49
- 238000000034 method Methods 0.000 title claims abstract description 15
- 239000004059 squalene synthase inhibitor Substances 0.000 title abstract description 25
- 229940123495 Squalene synthetase inhibitor Drugs 0.000 title abstract description 21
- 239000003638 chemical reducing agent Substances 0.000 title abstract description 3
- 108010022535 Farnesyl-Diphosphate Farnesyltransferase Proteins 0.000 claims abstract description 23
- 239000003112 inhibitor Substances 0.000 claims abstract description 19
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960003912 probucol Drugs 0.000 claims abstract description 15
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 14
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract description 13
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960003627 gemfibrozil Drugs 0.000 claims abstract description 12
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 10
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 claims abstract description 8
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 claims abstract description 8
- 230000007246 mechanism Effects 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- -1 poly(diallyldimethylammonium) Polymers 0.000 claims description 16
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 12
- 229920001268 Cholestyramine Polymers 0.000 claims description 10
- 229920002911 Colestipol Polymers 0.000 claims description 9
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims description 9
- 229960001214 clofibrate Drugs 0.000 claims description 9
- GMRWGQCZJGVHKL-UHFFFAOYSA-N colestipol Chemical compound ClCC1CO1.NCCNCCNCCNCCN GMRWGQCZJGVHKL-UHFFFAOYSA-N 0.000 claims description 9
- 229960002604 colestipol Drugs 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- 229960003512 nicotinic acid Drugs 0.000 claims description 7
- 235000001968 nicotinic acid Nutrition 0.000 claims description 7
- 239000011664 nicotinic acid Substances 0.000 claims description 7
- 229920000080 bile acid sequestrant Polymers 0.000 claims description 5
- WGESLFUSXZBFQF-UHFFFAOYSA-N n-methyl-n-prop-2-enylprop-2-en-1-amine Chemical class C=CCN(C)CC=C WGESLFUSXZBFQF-UHFFFAOYSA-N 0.000 claims description 5
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 4
- 229930193140 Neomycin Natural products 0.000 claims description 4
- 229920005654 Sephadex Polymers 0.000 claims description 4
- 239000012507 Sephadex™ Substances 0.000 claims description 4
- 229960004909 aminosalicylic acid Drugs 0.000 claims description 4
- 229960004927 neomycin Drugs 0.000 claims description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 3
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 150000001412 amines Chemical group 0.000 claims description 3
- 229960001767 dextrothyroxine Drugs 0.000 claims description 3
- LTMQZVLXCLQPCT-UHFFFAOYSA-N 1,1,6-trimethyltetralin Chemical compound C1CCC(C)(C)C=2C1=CC(C)=CC=2 LTMQZVLXCLQPCT-UHFFFAOYSA-N 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000055 hyoplipidemic effect Effects 0.000 claims 1
- 230000000871 hypocholesterolemic effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 13
- VWFJDQUYCIWHTN-YFVJMOTDSA-N 2-trans,6-trans-farnesyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-YFVJMOTDSA-N 0.000 description 10
- 239000003529 anticholesteremic agent Substances 0.000 description 10
- 229940127226 anticholesterol agent Drugs 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 9
- 229920002261 Corn starch Polymers 0.000 description 8
- 239000008120 corn starch Substances 0.000 description 8
- 229940099112 cornstarch Drugs 0.000 description 8
- VWFJDQUYCIWHTN-UHFFFAOYSA-N Farnesyl pyrophosphate Natural products CC(C)=CCCC(C)=CCCC(C)=CCOP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-UHFFFAOYSA-N 0.000 description 7
- 235000011180 diphosphates Nutrition 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 102000007330 LDL Lipoproteins Human genes 0.000 description 6
- 108010007622 LDL Lipoproteins Proteins 0.000 description 6
- ATZKAUGGNMSCCY-VVFNRDJMSA-N [(1r,2r,3r)-2-[(3e)-4,8-dimethylnona-3,7-dienyl]-2-methyl-3-[(1e,5e)-2,6,10-trimethylundeca-1,5,9-trienyl]cyclopropyl]methyl phosphono hydrogen phosphate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\[C@@H]1[C@@H](COP(O)(=O)OP(O)(O)=O)[C@]1(C)CC\C=C(/C)CCC=C(C)C ATZKAUGGNMSCCY-VVFNRDJMSA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000013543 active substance Substances 0.000 description 5
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical group [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 102000003960 Ligases Human genes 0.000 description 4
- 108090000364 Ligases Proteins 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- GVVPGTZRZFNKDS-YFHOEESVSA-N Geranyl diphosphate Natural products CC(C)=CCC\C(C)=C/COP(O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-YFHOEESVSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 150000001942 cyclopropanes Chemical class 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical compound CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- PQIOSYKVBBWRRI-UHFFFAOYSA-N methylphosphonyl difluoride Chemical group CP(F)(F)=O PQIOSYKVBBWRRI-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 150000003505 terpenes Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- RWIUTHWKQHRQNP-ZDVGBALWSA-N (9e,12e)-n-(1-phenylethyl)octadeca-9,12-dienamide Chemical compound CCCCC\C=C\C\C=C\CCCCCCCC(=O)NC(C)C1=CC=CC=C1 RWIUTHWKQHRQNP-ZDVGBALWSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- BDKQVCHNTAJNJR-UHFFFAOYSA-N 3,7,11-trimethyldodeca-2,6,10-trien-1-amine Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCN BDKQVCHNTAJNJR-UHFFFAOYSA-N 0.000 description 1
- NBYATBIMYLFITE-UHFFFAOYSA-N 3-[decyl(dimethyl)silyl]-n-[2-(4-methylphenyl)-1-phenylethyl]propanamide Chemical compound C=1C=CC=CC=1C(NC(=O)CC[Si](C)(C)CCCCCCCCCC)CC1=CC=C(C)C=C1 NBYATBIMYLFITE-UHFFFAOYSA-N 0.000 description 1
- FUSNOPLQVRUIIM-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide Chemical compound O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 FUSNOPLQVRUIIM-UHFFFAOYSA-N 0.000 description 1
- MXNQOXJLUJUCGE-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide;hydrochloride Chemical compound Cl.O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 MXNQOXJLUJUCGE-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- HPJYKMSFRBJOSW-JHSUYXJUSA-N Damsin Chemical compound C[C@H]1CC[C@H]2C(=C)C(=O)O[C@H]2[C@]2(C)C(=O)CC[C@@H]12 HPJYKMSFRBJOSW-JHSUYXJUSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VWFJDQUYCIWHTN-FBXUGWQNSA-N Farnesyl diphosphate Natural products CC(C)=CCC\C(C)=C/CC\C(C)=C/COP(O)(=O)OP(O)(O)=O VWFJDQUYCIWHTN-FBXUGWQNSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 108010026318 Geranyltranstransferase Proteins 0.000 description 1
- 102000013404 Geranyltranstransferase Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 208000006930 Pseudomyxoma Peritonei Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000000746 allylic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002484 anti-cholesterolemic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 229940096699 bile acid sequestrants Drugs 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940107170 cholestyramine resin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 150000002031 dolichols Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000002350 geranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
- 229950010293 imanixil Drugs 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229950008446 melinamide Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 description 1
- 229950009116 mevastatin Drugs 0.000 description 1
- BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 238000006456 reductive dimerization reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical class [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
HX24 Abstract COMBINATION OF A SQUALENE SYNTHETASE INHIBITOR AND OTHER TYPE OF SERUM CHOLESTEROL REDUCING AGENT AND METHOD FOR LOWERING SERUM CHOLESTEROL USING SUCH COMBINATION A pharmaceutical combination is provided which includes an inhibitor of the enzyme squalene synthetase and a pharmaceutical which reduces serum cholesterol by a mechanism other than inhibiting production of the enzyme HMG CoA reductase or the enzyme squalene synthetase, namely, an antihyperlipoproteinemic agent or antihyperlipemic agent, for example, probucol or gemfibrozil. A method for reducing serum cholesterol or inhibiting formation of or treating atherosclerosis using the above combination is also provided.
Description
)7~
COMBINATION OF SOUALENE SYNTHETASE
INHIBITOR AND OTHER TYPE OF SERUM
CHOLESTEROL REDUCING AGENT AND METHOD FOR
LOWERING SERUM CHOLESTEROL USING SUCH COMBINATION
The present invention relates to a combination of an inhibitor of squalene synthetase and a pharmaceutical which reduces serum cholesterol other than by inhib.ting squalene synthetase, and to a method for lowering serum cholesterol and/or preventing or treating atherosclerosis by administering such combination.
There are several different classes of compounds which have serum cholesterol lowering properties. Some of these compounds are inhibitors of the enzyme HMG CoA reductase which is essential in the production of cholesterol, such as mevastatin (disclosed in U. S. Patent No.
3,983,140), lovastatin also referred to as -mevinolin (disclosed in U. S. Patent No.
4,231,938), pravastatin (disclosed in U. S. Patent No. 4,346,227) and velostatin also referred to as synvinolin (disclosed in U. S. Patents Nos.
4,448,784 and 4,450,171).
7~
Other compounds which lower serum cholesterol may do so by an entirely different mechanism than the HMG CoA reductase inhibitors.
For example, serum cholesterol may be lowered through the use of bile acid seguestrants such as cholestyramine, colestipol, DEAE-Sephadex and poly(diallylmethylamine) derivatives (such as disclosed in U. S. Patents Nos. 4,759,923 and 4,027,009) or through the use of antihyperlipo-proteinemics such as probucol and gemfibrozilwhich apparently lower serum "low density lipoproteins" (LDL) and/or convert LDL into high density lipoproteins (HDL).
U. S. Patent No. 4,759,923 mentioned above discloses that poly(diallylmethylamine) derivatives which are bile salt sequestrants may be used in conjunction with drugs which reduce serum cholesterol by mechanisms other than sequestration, such as clofibrate, nicotinic acid, probucol, neomycin, p-aminosalicylic acid or mevinolin (also referred to as lovastatin).
Sgualene synthetase is a microsomal enzyme which catalyzes the reductive dimerization of two molecules of farnesyl pyrophosphate (FPP) in the presence of nicotinamide adenine dinucleotide phosphate ~reduced form) (NADPH) to form squalene (Poulter, C. D.; Rilling, H. C., in "Biosynthesis of Isoprenoid Compounds", Vol. I, Chapter 8, pp.
413-441, J. Wiley and Sons, 1981 and references therein). This enzyme is the first committed step of the de novo cholesterol biosynthetic pathway.
The selective inhibition of this step should allow the essential pathways to isopentenyl tRNA, 7~
ubiquinone, and dolichol to proceed unimpeded.
Squalene synthetase, along with HMG-CoA reductase has been shown to be down-regulated by receptor mediated LDL uptake (Faust, J. R.; Goldstein, J. L.; Brown, M. S. Proc. Nat. Acad. Sci. USA, 1979, 76, 5018-5022), lending credence to the proposal that inhibiting squalene synthetase will lead to an up-regulation of LDL receptor levels, as h~s been demonstrated for HMG-CoA reductase, and thus ultimately should be useful for the treatment and prevention of hypercholesterolemia and atherosclerosis.
One approach to inhibitors of squalene synthetase is to design analogs of the substrate FPP. It is clear from the literature that the pyrophosphate moiety is essential for binding to the enzyme. However, such pyrophosphates are unsuitable as components of pharmacological agents due to their chemical and enzymatic lability towards allylic C-O cleavage, as well as their susceptibility to metabolism by phosphatases.
P. Ortiz de Montellano et al. in J. Med. Chem., 1977, 20, 243-249 describe the preparation of a series of substituted terpenoid pyrophosphates (Table A), and have shown these to be competitive inhibitors of the squalene synthetase enzyme. These substances retain the unstable allylic pyrophosphate moiety of FPP.
6~
Table A
'"j , \~ o 10 N X Y Z_ Corey and Volante, J. Am. Chem. Soc. 1976, 98, 1291-3, have prepared FPP analog A and presqualene pyrophosphate (PSQ-PP) analog B as inhibitors of squalene biosynthesis. (Presqualene pyrophosphate i8 an intermediate in the conversion of FPP to squalene). These inhibitors possess methylene groups in place of the allylic oxygen moiety of FPP and PSQ-PP, but still retain the chemically and enzymatically unstable pyrophosphate linkage.
2~Q'7~
_5_ ~ ~ r ~/\~--A X = CH2 FPP X = O
/ ~\ O/ ~~
B X = CH2 PSQ-PP X = O
Poulter and co-workers have prepared cyclopropane C (Sandifer, R. M., et al., J. Am. Chem. Soc. 1982, 104, 7376-8) which in the presence of inorganic pyrophosphate is an intermediate analog inhibitor of the enzyme squalene synthetase.
;~Gi7~
Me 10 ~
Altman and co-workers, Bertolino, A., et al., Biochim. BioPhys. Acta. 1978, 530, 17-23, lS reported that farnesyl amine and related derivatives D inhibit squalene synthetase, but provide evidence that this inhibition is non-specific and probably related to membrane disruption.
NH-R
R = H, CH2CH2OH, CH2CH2OCH3 Poulter, C.D., et al, J. Org. Chem., 1986, 51, 4768, prepared compound ~ in a demonstration of a synthetic method, but did not report any biological data.
~ O_~ Q-OH
~ ~H
3~ E
Poulter, C.D., Stremler, K.~., J.A.C.S., 1987 109 5542 describes the synthesis and biological evaluation of compounds having structure F. These compounds were evaluated as alternative substrates for avian liver farnesyl diphosphate and lemon peel cyclase.
~ ~O-~-X-~-OH
2 0 F X=CH2 CF2 McClard, R. W. and Poulter, C. D., et al., J A C S 1987 109 5544 reported that phosphinylphosphonates G and H were competitive inhibitors of the 1'-4-condensation between isopentenyl diphosphate and geranyl diphosphate catalyzed by avian liver farnesyl diphosphate synthetase. Phosphinylphosphonates G and H had Ki's of l9~M and 71~M, respectively. They also reported the speculative isolation of the farnesyl phosphinylphosphonate I, and the geranyl phosphinylphosphonate J from the enzymatic reaction of G with geranyl pyrophosphate or dimethylallyl ~Q7~
pyrophosphate, respectively. The structures of I
and J were tentatively assigned based on relative TLC mobilities. They hypothesized that I could be a potentlal inhibitor of squalene synthetase.
s ~ - ' -- o--G
~ O-~ o ~ o_ b ~37~4~
_g_ Capson, T.L., PhD dissertation, June 1987, Dept. of Medicinal Chemistry, the University of Utah, Abstract, Table of Contents, pp. 16, 17, 40-43, 48-S1, Summary, discloses cyclopropanes of the structure 0_ ' o~ 1-as intermediate analog inhibitors of squalene synthetase.
S. A. Biller et al., Journal of Medicinal Chemistry, 1988, Vol. 31, No. 10, pp 1869 to 1871 disclose that isoprenoid (phosphinylmethyl) phosphonates (PMPs) inhibit squalene synthetase.
These phosphonates have the structures Rl-~-CH2-~-O- Rl-~-CF2-~-O-2a-d 3a,b Rl 2 ~ HX24 10 c In accordance with the present invention, a pharmaceutical combination is provided for use in reducing serum cholesterol and in inhibiting formation of,or treating atherosclerosis, which combination is formed of an inhibitor of the enzyme squalene synthetase and a pharmaceutical (also referred to as other serum cholesterol lowering agent) which reduces serum cholesterol and/or inhibits cholesterol biosynthesis by a mechanism other than by inhibiting production of the enzyme squalene synthetase or 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA~ reductase, such as a bile salt sequestrant or antihyperlipoproteinemic agent which inhibits formation of LDL or converts LDL to HDL.
The squalene synthetase inhibitor will be employed in a weight ratio to the "pharmaceutical" of within the range of from about 0.001:1 to about 1000:1 and preferably from about 0.05:1 to about 100:1.
In addition, in accordance with the present invention, a method is provided for lowering serum cholesterol or inhibiting formation of or treating ~)7~
atherosclerosis wherein a therapeutically effective amount of the above combination is systemically, such as orally or parenterally, administered over a prolonged period.
The combination of the squalene synthetase inhibitor and other serum cholesterol lowering agent, as described above, is a surprising and unique concept in inhibiting or treating elevated cholesterol and/or atherosclerosis in that it may provide additional anticholesterolemic effects over that which may be obtained using each of the components of the combination alone. In addition, the combination of the invention which includes compounds with different mechanisms of action, may be used to effectively treat cholesterol-related diseases of multiple etiology.
The squalene synthetase inhibitors suitable for use herein include, but are not limited to, those disclosed by Biller et al., supra, including isoprenoid (phosphinylmethyl)phosphonates such as those of the formula R1_p-CH2-P-0 R1-P-CF2-P-0 O O O O
I II
Rl :
~1 ~~
c d ~
including the triacids thereof, triesters thereof and tripotassium and trisodium salts thereof as well a8 other squalene synthetase inhibitors disclosed in pending U.S. patent application Serial No. 141,744, filed January 11, 1988.
In addition, other squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by P. Ortiz de Montellano et al., J. Med. Chem.; 1977, 20, 243-249, the farnesyl diphosphate analog A and presgualene pyrophosphate (PSQ-PP) analogs as disclo8ed by Corey and Volante, J. Am. Chem. Soc.
1976, 98, 1291-1293, phosphinylphosphonates reported by McClard, R. W. et al., J.A.C.S., 1987, 109, 5544 and cyclopropanes reported by Capson, T.L., PhD dissertation, June, 1987, Dept. Med.
Chem. U. of Utah, abstract, Table of Contents, pp. 16, 17, 40-43, 48-51, Summary, as well as other known squalene synthetase inhibitors.
The "pharmaceutical" or other serum cholesterol lowering agents which function other 7 ~ ~
than by inhibiting the enzyme HMG CoA reductase or squalene synthetase suitable for use herein include, but are not limited to, antihyper-lipoproteinemic agents such as probucol, and gemfibrozil and related compounds as disclosed in U. S. Patent No. 3,674,836, probucol and gemfibrozil being preferred, bile acid sequestrants such as cholestyramine, colestipol and DEAE-Sephadex (Secholex~, Polidexide~), as well as clofibrate, lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402) tetrahydrolipstatin (THL), istigmastanyl-phosphorylcholine (SPC, Roche), aminocyclodextrin ~Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (di-substituted urea derivatives), nicotinic acid, neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives such as disclosed in U. S. Patent No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in U. S.
Patent No. 4,027,009, and other known serum cholesterol lowering agents which lower cholesterol through a mechanism other than by the inhibition of the enzyme HMG CoA reductase or squalene synthetase.
Preferred are combinations of any of the isoprenoid (phosphinylmethyl) phosphonates disclosed by Biller et al., supra with probucol or gemfibrozil.
The disclosure of the above-mentioned patents and patent applications are incorporated herein by reference.
X~3~)7~1 In carrying out the method of the present invention, the combination of the invention may be administered to mammalian species, such as monkeys, dogs, cats, rats, humans, etc. and as such may be incorporated in a conventional systemic dosage form, such as a tablet, capsule, elixir or injectable. The above dosage forms will also include the necessary carrier material, excipient, lubricant, buffer, antibacterial, bulking agent (such as mannitol), anti-oxidants (ascorbic acid or sodium bisulfite) or the like. Oral dosage forms are preferred, although parenteral forms are quite satisfactory as well.
The dose administered must be carefully adjusted according to age, weight and condition of the patient, as well as the route of admini~tration, dosage form and regimen and the desired result.
Thus, for oral administration, a satis-factory result may be obtained employing the squalene synthetase inhibitor in dosages in an amount within the range of from about 10 to about 2000 mg and preferably from about 25 to about 200 mg in combination with the other serum cholesterol lowering agent in dosages normally employed as indicated in the Physician's Desk Reference, for each of such agents such as in an amount within the range of from about 2 mg to about 7500 mg and preferably from about 2 mg to about 4000 mg with the squalene synthetase inhibitor and other serum cholesterol lowering agent being employed together in the same oral dosage form or in separate oral dosage forms taken at the same time.
2~36Ji7~
A preferred oral dosage form, such as tablets or capsules, will contain the squalene synthetase inhibitor in an amount of from about 10 to about 500 mg, preferably from about 25 to about 200 mg, and the other serum cholesterol lowering agent in an amount of from about 2 to about 3000 mg, preferably from about 2 to about 2000 mg.
The composition described above may be administered in the dosage forms as described above in single or divided doses of one to four times daily. It may be advisable to start a patient on a low dose combination and work up gradually to a high dose combination.
Tablets of various sizes can be prepared, e.g., of about 2 to 2000 mg in total weight, containing one or both of the active substances in the ranges described above, with the remainder being a physiologically acceptable carrier of other materials according to accepted pharmaceutical practice. These tablets can, of course, be scored to provide for fractional doses. Gelatin capsules can be similarly formulated.
Liquid formulations can also be prepared by dissolving or suspending one or the combination of active substances in a conventional liquid vehicle acceptable for pharmaceutical administration so as to provide the desired dosage in one to four teaspoonsful.
Such dosage forms can be administered to the patient on a regimen of one to four doses per day.
According to another modification, in order to more finely regulate the dosage schedule, the active substances may be administered separately in . . .
.
7~
individual dosage units at the same time or carefully coordinated times. Since blood levels are built up and maintained by a regulated schedule of administration, the same result is achieved by S the simultaneous presence of the two substances.
The respective substances can be individually formulated in separate unit dosage forms in a manner similar to that described above.
Fixed combinations of squalene synthetase inhibitor and other serum cholesterol lowering agent are more convenient and are preferred, especially in tablet or capsule form for oral administration.
In formulating the compositions, the active substances, in the amounts described above, are compounded according to accepted pharmaceutical practice with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in the particular type of unit dosage form.
Illustrative of the adjuvants which may be incorporated in tablets are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as dicalcium phosphate or cellulose; a disintegrating agent such as corn starch, potato starch, alginic acid or the like; a lubricant such as stearic acid or magnesium stearate; a sweetening agent such as sucrose, aspartame, lactose or saccharin; a flavoring agent such as orange, peppermint, oil of wintergreen or cherry. When the dosage unit form is a capsule, it may contain in addition to materials of the above type a liquid carrier such as a fatty oil. Various ;~07~i4~
other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets or capsules may be coated with shellac, sugar or both. A syrup of elixir may contain the active compound~ water, alcohol or the like as the carrier, glycerol as solubilizer, sucrose as sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange.
Some of the active substances described:
above form commonly known, pharmaceutically acceptable salts such as alkali metal and other common basic salts or acid addition salts, etc.
References to the base substances are therefore intended to include those common salts known to be substantially equivalent to the parent compound.
The formulations as described above will be administered for a prolonged period, that i6, for as long as the potential for elevated serum cholesterol and atherosclerosis remains or the symptoms continue. Sustained release forms of such formulations which may provide such amounts biweekly, weekly, monthly and the like may also be employed. A dosing period of at least one to two weeks are required to achieve minimal benefit.
;~Q7~i4:
The following Examples represent preferred embodiments of the present invention. A11 temperatures are expressed in degrees Centigrade unless otherwise indicated and all mesh sizes are S U.S. Standard ASTME.
Exam~le 1 A squalene synthetase inhibitor formulation in the form of tablets having the following composition was prepared as described below.
In~redient Weiqht (mg) (E,E)-[[hydroxy(4,8,12-trimethyl-100 mg 3,7,11-tridecatrienyl~phosphinyl]-methyl]phosphonic acid tripotassium salt (squalene synthetase inhibitor prepared as described by Biller et al. supra) Cornstarch 50 mg 20 Gelatin 7.5 mg Avicel (microcrystalline 25 mg cellulose) Magnesium stearate 2.5 mg 185 mg The tablets are prepared from sufficient bulk quantities by mixing the tripotassium salt and cornstarch with an aqueous solution of the gelatin. The mixture is dried and ground to a fine powder. The Avicel and then the magnesium stearate are admixed with granulation. The mixture is compressed in a tablet press to form tablets each containing lO0 mg of active ingredient.
f~ 7~
Probucol tablets containing 25C mg probucol are prepared employing conventional procedures containing the following additional ingredients as set out in the 1988 PDR: corn starch, ethyl S cellulose, glycerin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose 2910, iron oxide, lactose, magnesium stearate, microcrystalline cellulose, polysorbate 80, talc and titanium dioxide.
The squalene synthetase inhibitor and probucol tablets may be administered as a combination in accordance with the teachings of the present invention to lower serum cholesterol and/or treat atherosclerosis. In addition, the squalene synthetase inhibitor and probucol tablets may be ground up into powders and used together in a single capsule.
Exam~le 2 Tablets each containing the following ingredients:
. "~ . :
4~
Inaredient Wei~ht (mq) (E,E)-[difluoro[hydroxy(4,8,12-100 mg trimethyl-3,7,11-tridecatrienyl)-phosphinyl]methyl]phosphonic acid tripotassium salt (squalene synthetase inhibitor prepared as described by Biller et al. supra) Avicel 112.5 mg Lactose 113 mg 10 Cornstarch 17.5 mg Stearic Acid 7 mq 350 mg are prepared from sufficient bulk quantities by slugging the squalene synthetase inhibitor, Avicel, and a portion of the stearic acid. The slugs are ground and passed through a #2 screen and then mixed with the lactose, cornstarch, and the remainder of stearic acid. The mixture is compressed into 350 mg capsule shaped tablets in a tablet press. The tablets are scored for dividing in half.
Capsules containing 300 mg gemfibrozil are prepared employing conventional pharmaceutical techniques containing the following additional ingredients as described in the 1988 PDR:
polysorbate 80 NF, starch NF and silica gel.
The squalene synthetase inhibitor tablet and gemfibrozil capsule may be administered as a combination or the squalene synthetase inhibitor tablet may be ground into a powder and used in a single capsule containing gemfibrozil to lower 2BC~7{i41 serum cholesterol and/or treat atherosclerosis in accordance with the teachings of the present invention.
Exam~les 3 A formulation in the form of tablets having the following composition was prepared as described in Example 1.
10 Ingredient Weiqht (mq~
(E,E,E)-[difluoro[hydroxy(4,8,12-100 mg trimethyl-1,3,7,11-tridecate-traenyl)phosphinyl]methyl]-phosphonic acid tripotassium salt (squalene synthetase inhibitor prepared as described by Biller et al. supra) Cornstarch 50 mg Gelatin 7.5 mg 20 Avicel (microcrystalline cellulose) 25 mg Magnesium stearate 2.5 mg 185 mg The above squalene synthetase inhibitor tablets may be employed in combination with clofibrate capsules containing 500 mg clofibrate and inactive ingredients including color, and gelatin as described in the 1988 PDR. The squalene synthetase inhibitor and clofibrate may be employed in separate dosage forms or combined in a single capsule form to lower elevated serum cholesterol or treat atherosclerosis in accordance with the present invention.
Z~7~
Examples 4 to 6 Sgualene synthetase inhibitor tablets described in Examples 1, 2 and 3, respectively, may be employed in combination with cholestyramine resin containing 4 g cholestyramine, acacia, citric acid, color, flavor, polysorbate 80, propylene glycol alginate and sucrose as described in the 1988 PDR. The squalene synthetase inhibitor and cholestyramine may be employed in separate dosage forms or combined in a single capsule form to lower serum cholesterol or treat atherosclerosis in accordance with the present invention..
Exam~les 7 to 10 Squalene synthetase inhibitor tablets, prepared as described in Examples l, 2 and 3, respectively, may be employed in combination with nicotinic acid, colestipol, dextrothyroxine or other serum cholesterol lowering agent in accordance with the teaching of the present invention to lower cholesterol or treat atherosclerosis.
It will also be appreciated that any of the sgualene synthetase inhibitors disclosed in the Biller et al. paper and in pending U.S. patent application Serial No. 141,744 may be employed in combination with any of the serum cholesterol lowering agents disclosed herein in accordance wi~h the present invention.
COMBINATION OF SOUALENE SYNTHETASE
INHIBITOR AND OTHER TYPE OF SERUM
CHOLESTEROL REDUCING AGENT AND METHOD FOR
LOWERING SERUM CHOLESTEROL USING SUCH COMBINATION
The present invention relates to a combination of an inhibitor of squalene synthetase and a pharmaceutical which reduces serum cholesterol other than by inhib.ting squalene synthetase, and to a method for lowering serum cholesterol and/or preventing or treating atherosclerosis by administering such combination.
There are several different classes of compounds which have serum cholesterol lowering properties. Some of these compounds are inhibitors of the enzyme HMG CoA reductase which is essential in the production of cholesterol, such as mevastatin (disclosed in U. S. Patent No.
3,983,140), lovastatin also referred to as -mevinolin (disclosed in U. S. Patent No.
4,231,938), pravastatin (disclosed in U. S. Patent No. 4,346,227) and velostatin also referred to as synvinolin (disclosed in U. S. Patents Nos.
4,448,784 and 4,450,171).
7~
Other compounds which lower serum cholesterol may do so by an entirely different mechanism than the HMG CoA reductase inhibitors.
For example, serum cholesterol may be lowered through the use of bile acid seguestrants such as cholestyramine, colestipol, DEAE-Sephadex and poly(diallylmethylamine) derivatives (such as disclosed in U. S. Patents Nos. 4,759,923 and 4,027,009) or through the use of antihyperlipo-proteinemics such as probucol and gemfibrozilwhich apparently lower serum "low density lipoproteins" (LDL) and/or convert LDL into high density lipoproteins (HDL).
U. S. Patent No. 4,759,923 mentioned above discloses that poly(diallylmethylamine) derivatives which are bile salt sequestrants may be used in conjunction with drugs which reduce serum cholesterol by mechanisms other than sequestration, such as clofibrate, nicotinic acid, probucol, neomycin, p-aminosalicylic acid or mevinolin (also referred to as lovastatin).
Sgualene synthetase is a microsomal enzyme which catalyzes the reductive dimerization of two molecules of farnesyl pyrophosphate (FPP) in the presence of nicotinamide adenine dinucleotide phosphate ~reduced form) (NADPH) to form squalene (Poulter, C. D.; Rilling, H. C., in "Biosynthesis of Isoprenoid Compounds", Vol. I, Chapter 8, pp.
413-441, J. Wiley and Sons, 1981 and references therein). This enzyme is the first committed step of the de novo cholesterol biosynthetic pathway.
The selective inhibition of this step should allow the essential pathways to isopentenyl tRNA, 7~
ubiquinone, and dolichol to proceed unimpeded.
Squalene synthetase, along with HMG-CoA reductase has been shown to be down-regulated by receptor mediated LDL uptake (Faust, J. R.; Goldstein, J. L.; Brown, M. S. Proc. Nat. Acad. Sci. USA, 1979, 76, 5018-5022), lending credence to the proposal that inhibiting squalene synthetase will lead to an up-regulation of LDL receptor levels, as h~s been demonstrated for HMG-CoA reductase, and thus ultimately should be useful for the treatment and prevention of hypercholesterolemia and atherosclerosis.
One approach to inhibitors of squalene synthetase is to design analogs of the substrate FPP. It is clear from the literature that the pyrophosphate moiety is essential for binding to the enzyme. However, such pyrophosphates are unsuitable as components of pharmacological agents due to their chemical and enzymatic lability towards allylic C-O cleavage, as well as their susceptibility to metabolism by phosphatases.
P. Ortiz de Montellano et al. in J. Med. Chem., 1977, 20, 243-249 describe the preparation of a series of substituted terpenoid pyrophosphates (Table A), and have shown these to be competitive inhibitors of the squalene synthetase enzyme. These substances retain the unstable allylic pyrophosphate moiety of FPP.
6~
Table A
'"j , \~ o 10 N X Y Z_ Corey and Volante, J. Am. Chem. Soc. 1976, 98, 1291-3, have prepared FPP analog A and presqualene pyrophosphate (PSQ-PP) analog B as inhibitors of squalene biosynthesis. (Presqualene pyrophosphate i8 an intermediate in the conversion of FPP to squalene). These inhibitors possess methylene groups in place of the allylic oxygen moiety of FPP and PSQ-PP, but still retain the chemically and enzymatically unstable pyrophosphate linkage.
2~Q'7~
_5_ ~ ~ r ~/\~--A X = CH2 FPP X = O
/ ~\ O/ ~~
B X = CH2 PSQ-PP X = O
Poulter and co-workers have prepared cyclopropane C (Sandifer, R. M., et al., J. Am. Chem. Soc. 1982, 104, 7376-8) which in the presence of inorganic pyrophosphate is an intermediate analog inhibitor of the enzyme squalene synthetase.
;~Gi7~
Me 10 ~
Altman and co-workers, Bertolino, A., et al., Biochim. BioPhys. Acta. 1978, 530, 17-23, lS reported that farnesyl amine and related derivatives D inhibit squalene synthetase, but provide evidence that this inhibition is non-specific and probably related to membrane disruption.
NH-R
R = H, CH2CH2OH, CH2CH2OCH3 Poulter, C.D., et al, J. Org. Chem., 1986, 51, 4768, prepared compound ~ in a demonstration of a synthetic method, but did not report any biological data.
~ O_~ Q-OH
~ ~H
3~ E
Poulter, C.D., Stremler, K.~., J.A.C.S., 1987 109 5542 describes the synthesis and biological evaluation of compounds having structure F. These compounds were evaluated as alternative substrates for avian liver farnesyl diphosphate and lemon peel cyclase.
~ ~O-~-X-~-OH
2 0 F X=CH2 CF2 McClard, R. W. and Poulter, C. D., et al., J A C S 1987 109 5544 reported that phosphinylphosphonates G and H were competitive inhibitors of the 1'-4-condensation between isopentenyl diphosphate and geranyl diphosphate catalyzed by avian liver farnesyl diphosphate synthetase. Phosphinylphosphonates G and H had Ki's of l9~M and 71~M, respectively. They also reported the speculative isolation of the farnesyl phosphinylphosphonate I, and the geranyl phosphinylphosphonate J from the enzymatic reaction of G with geranyl pyrophosphate or dimethylallyl ~Q7~
pyrophosphate, respectively. The structures of I
and J were tentatively assigned based on relative TLC mobilities. They hypothesized that I could be a potentlal inhibitor of squalene synthetase.
s ~ - ' -- o--G
~ O-~ o ~ o_ b ~37~4~
_g_ Capson, T.L., PhD dissertation, June 1987, Dept. of Medicinal Chemistry, the University of Utah, Abstract, Table of Contents, pp. 16, 17, 40-43, 48-S1, Summary, discloses cyclopropanes of the structure 0_ ' o~ 1-as intermediate analog inhibitors of squalene synthetase.
S. A. Biller et al., Journal of Medicinal Chemistry, 1988, Vol. 31, No. 10, pp 1869 to 1871 disclose that isoprenoid (phosphinylmethyl) phosphonates (PMPs) inhibit squalene synthetase.
These phosphonates have the structures Rl-~-CH2-~-O- Rl-~-CF2-~-O-2a-d 3a,b Rl 2 ~ HX24 10 c In accordance with the present invention, a pharmaceutical combination is provided for use in reducing serum cholesterol and in inhibiting formation of,or treating atherosclerosis, which combination is formed of an inhibitor of the enzyme squalene synthetase and a pharmaceutical (also referred to as other serum cholesterol lowering agent) which reduces serum cholesterol and/or inhibits cholesterol biosynthesis by a mechanism other than by inhibiting production of the enzyme squalene synthetase or 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA~ reductase, such as a bile salt sequestrant or antihyperlipoproteinemic agent which inhibits formation of LDL or converts LDL to HDL.
The squalene synthetase inhibitor will be employed in a weight ratio to the "pharmaceutical" of within the range of from about 0.001:1 to about 1000:1 and preferably from about 0.05:1 to about 100:1.
In addition, in accordance with the present invention, a method is provided for lowering serum cholesterol or inhibiting formation of or treating ~)7~
atherosclerosis wherein a therapeutically effective amount of the above combination is systemically, such as orally or parenterally, administered over a prolonged period.
The combination of the squalene synthetase inhibitor and other serum cholesterol lowering agent, as described above, is a surprising and unique concept in inhibiting or treating elevated cholesterol and/or atherosclerosis in that it may provide additional anticholesterolemic effects over that which may be obtained using each of the components of the combination alone. In addition, the combination of the invention which includes compounds with different mechanisms of action, may be used to effectively treat cholesterol-related diseases of multiple etiology.
The squalene synthetase inhibitors suitable for use herein include, but are not limited to, those disclosed by Biller et al., supra, including isoprenoid (phosphinylmethyl)phosphonates such as those of the formula R1_p-CH2-P-0 R1-P-CF2-P-0 O O O O
I II
Rl :
~1 ~~
c d ~
including the triacids thereof, triesters thereof and tripotassium and trisodium salts thereof as well a8 other squalene synthetase inhibitors disclosed in pending U.S. patent application Serial No. 141,744, filed January 11, 1988.
In addition, other squalene synthetase inhibitors suitable for use herein include the terpenoid pyrophosphates disclosed by P. Ortiz de Montellano et al., J. Med. Chem.; 1977, 20, 243-249, the farnesyl diphosphate analog A and presgualene pyrophosphate (PSQ-PP) analogs as disclo8ed by Corey and Volante, J. Am. Chem. Soc.
1976, 98, 1291-1293, phosphinylphosphonates reported by McClard, R. W. et al., J.A.C.S., 1987, 109, 5544 and cyclopropanes reported by Capson, T.L., PhD dissertation, June, 1987, Dept. Med.
Chem. U. of Utah, abstract, Table of Contents, pp. 16, 17, 40-43, 48-51, Summary, as well as other known squalene synthetase inhibitors.
The "pharmaceutical" or other serum cholesterol lowering agents which function other 7 ~ ~
than by inhibiting the enzyme HMG CoA reductase or squalene synthetase suitable for use herein include, but are not limited to, antihyper-lipoproteinemic agents such as probucol, and gemfibrozil and related compounds as disclosed in U. S. Patent No. 3,674,836, probucol and gemfibrozil being preferred, bile acid sequestrants such as cholestyramine, colestipol and DEAE-Sephadex (Secholex~, Polidexide~), as well as clofibrate, lipostabil (Rhone-Poulenc), Eisai E-5050 (an N-substituted ethanolamine derivative), imanixil (HOE-402) tetrahydrolipstatin (THL), istigmastanyl-phosphorylcholine (SPC, Roche), aminocyclodextrin ~Tanabe Seiyoku), Ajinomoto AJ-814 (azulene derivative), melinamide (Sumitomo), Sandoz 58-035, American Cyanamid CL-277,082 and CL-283,546 (di-substituted urea derivatives), nicotinic acid, neomycin, p-aminosalicylic acid, aspirin, poly(diallylmethylamine) derivatives such as disclosed in U. S. Patent No. 4,759,923, quaternary amine poly(diallyldimethylammonium chloride) and ionenes such as disclosed in U. S.
Patent No. 4,027,009, and other known serum cholesterol lowering agents which lower cholesterol through a mechanism other than by the inhibition of the enzyme HMG CoA reductase or squalene synthetase.
Preferred are combinations of any of the isoprenoid (phosphinylmethyl) phosphonates disclosed by Biller et al., supra with probucol or gemfibrozil.
The disclosure of the above-mentioned patents and patent applications are incorporated herein by reference.
X~3~)7~1 In carrying out the method of the present invention, the combination of the invention may be administered to mammalian species, such as monkeys, dogs, cats, rats, humans, etc. and as such may be incorporated in a conventional systemic dosage form, such as a tablet, capsule, elixir or injectable. The above dosage forms will also include the necessary carrier material, excipient, lubricant, buffer, antibacterial, bulking agent (such as mannitol), anti-oxidants (ascorbic acid or sodium bisulfite) or the like. Oral dosage forms are preferred, although parenteral forms are quite satisfactory as well.
The dose administered must be carefully adjusted according to age, weight and condition of the patient, as well as the route of admini~tration, dosage form and regimen and the desired result.
Thus, for oral administration, a satis-factory result may be obtained employing the squalene synthetase inhibitor in dosages in an amount within the range of from about 10 to about 2000 mg and preferably from about 25 to about 200 mg in combination with the other serum cholesterol lowering agent in dosages normally employed as indicated in the Physician's Desk Reference, for each of such agents such as in an amount within the range of from about 2 mg to about 7500 mg and preferably from about 2 mg to about 4000 mg with the squalene synthetase inhibitor and other serum cholesterol lowering agent being employed together in the same oral dosage form or in separate oral dosage forms taken at the same time.
2~36Ji7~
A preferred oral dosage form, such as tablets or capsules, will contain the squalene synthetase inhibitor in an amount of from about 10 to about 500 mg, preferably from about 25 to about 200 mg, and the other serum cholesterol lowering agent in an amount of from about 2 to about 3000 mg, preferably from about 2 to about 2000 mg.
The composition described above may be administered in the dosage forms as described above in single or divided doses of one to four times daily. It may be advisable to start a patient on a low dose combination and work up gradually to a high dose combination.
Tablets of various sizes can be prepared, e.g., of about 2 to 2000 mg in total weight, containing one or both of the active substances in the ranges described above, with the remainder being a physiologically acceptable carrier of other materials according to accepted pharmaceutical practice. These tablets can, of course, be scored to provide for fractional doses. Gelatin capsules can be similarly formulated.
Liquid formulations can also be prepared by dissolving or suspending one or the combination of active substances in a conventional liquid vehicle acceptable for pharmaceutical administration so as to provide the desired dosage in one to four teaspoonsful.
Such dosage forms can be administered to the patient on a regimen of one to four doses per day.
According to another modification, in order to more finely regulate the dosage schedule, the active substances may be administered separately in . . .
.
7~
individual dosage units at the same time or carefully coordinated times. Since blood levels are built up and maintained by a regulated schedule of administration, the same result is achieved by S the simultaneous presence of the two substances.
The respective substances can be individually formulated in separate unit dosage forms in a manner similar to that described above.
Fixed combinations of squalene synthetase inhibitor and other serum cholesterol lowering agent are more convenient and are preferred, especially in tablet or capsule form for oral administration.
In formulating the compositions, the active substances, in the amounts described above, are compounded according to accepted pharmaceutical practice with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in the particular type of unit dosage form.
Illustrative of the adjuvants which may be incorporated in tablets are the following: a binder such as gum tragacanth, acacia, corn starch or gelatin; an excipient such as dicalcium phosphate or cellulose; a disintegrating agent such as corn starch, potato starch, alginic acid or the like; a lubricant such as stearic acid or magnesium stearate; a sweetening agent such as sucrose, aspartame, lactose or saccharin; a flavoring agent such as orange, peppermint, oil of wintergreen or cherry. When the dosage unit form is a capsule, it may contain in addition to materials of the above type a liquid carrier such as a fatty oil. Various ;~07~i4~
other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets or capsules may be coated with shellac, sugar or both. A syrup of elixir may contain the active compound~ water, alcohol or the like as the carrier, glycerol as solubilizer, sucrose as sweetening agent, methyl and propyl parabens as preservatives, a dye and a flavoring such as cherry or orange.
Some of the active substances described:
above form commonly known, pharmaceutically acceptable salts such as alkali metal and other common basic salts or acid addition salts, etc.
References to the base substances are therefore intended to include those common salts known to be substantially equivalent to the parent compound.
The formulations as described above will be administered for a prolonged period, that i6, for as long as the potential for elevated serum cholesterol and atherosclerosis remains or the symptoms continue. Sustained release forms of such formulations which may provide such amounts biweekly, weekly, monthly and the like may also be employed. A dosing period of at least one to two weeks are required to achieve minimal benefit.
;~Q7~i4:
The following Examples represent preferred embodiments of the present invention. A11 temperatures are expressed in degrees Centigrade unless otherwise indicated and all mesh sizes are S U.S. Standard ASTME.
Exam~le 1 A squalene synthetase inhibitor formulation in the form of tablets having the following composition was prepared as described below.
In~redient Weiqht (mg) (E,E)-[[hydroxy(4,8,12-trimethyl-100 mg 3,7,11-tridecatrienyl~phosphinyl]-methyl]phosphonic acid tripotassium salt (squalene synthetase inhibitor prepared as described by Biller et al. supra) Cornstarch 50 mg 20 Gelatin 7.5 mg Avicel (microcrystalline 25 mg cellulose) Magnesium stearate 2.5 mg 185 mg The tablets are prepared from sufficient bulk quantities by mixing the tripotassium salt and cornstarch with an aqueous solution of the gelatin. The mixture is dried and ground to a fine powder. The Avicel and then the magnesium stearate are admixed with granulation. The mixture is compressed in a tablet press to form tablets each containing lO0 mg of active ingredient.
f~ 7~
Probucol tablets containing 25C mg probucol are prepared employing conventional procedures containing the following additional ingredients as set out in the 1988 PDR: corn starch, ethyl S cellulose, glycerin, hydroxypropyl cellulose, hydroxypropylmethyl cellulose 2910, iron oxide, lactose, magnesium stearate, microcrystalline cellulose, polysorbate 80, talc and titanium dioxide.
The squalene synthetase inhibitor and probucol tablets may be administered as a combination in accordance with the teachings of the present invention to lower serum cholesterol and/or treat atherosclerosis. In addition, the squalene synthetase inhibitor and probucol tablets may be ground up into powders and used together in a single capsule.
Exam~le 2 Tablets each containing the following ingredients:
. "~ . :
4~
Inaredient Wei~ht (mq) (E,E)-[difluoro[hydroxy(4,8,12-100 mg trimethyl-3,7,11-tridecatrienyl)-phosphinyl]methyl]phosphonic acid tripotassium salt (squalene synthetase inhibitor prepared as described by Biller et al. supra) Avicel 112.5 mg Lactose 113 mg 10 Cornstarch 17.5 mg Stearic Acid 7 mq 350 mg are prepared from sufficient bulk quantities by slugging the squalene synthetase inhibitor, Avicel, and a portion of the stearic acid. The slugs are ground and passed through a #2 screen and then mixed with the lactose, cornstarch, and the remainder of stearic acid. The mixture is compressed into 350 mg capsule shaped tablets in a tablet press. The tablets are scored for dividing in half.
Capsules containing 300 mg gemfibrozil are prepared employing conventional pharmaceutical techniques containing the following additional ingredients as described in the 1988 PDR:
polysorbate 80 NF, starch NF and silica gel.
The squalene synthetase inhibitor tablet and gemfibrozil capsule may be administered as a combination or the squalene synthetase inhibitor tablet may be ground into a powder and used in a single capsule containing gemfibrozil to lower 2BC~7{i41 serum cholesterol and/or treat atherosclerosis in accordance with the teachings of the present invention.
Exam~les 3 A formulation in the form of tablets having the following composition was prepared as described in Example 1.
10 Ingredient Weiqht (mq~
(E,E,E)-[difluoro[hydroxy(4,8,12-100 mg trimethyl-1,3,7,11-tridecate-traenyl)phosphinyl]methyl]-phosphonic acid tripotassium salt (squalene synthetase inhibitor prepared as described by Biller et al. supra) Cornstarch 50 mg Gelatin 7.5 mg 20 Avicel (microcrystalline cellulose) 25 mg Magnesium stearate 2.5 mg 185 mg The above squalene synthetase inhibitor tablets may be employed in combination with clofibrate capsules containing 500 mg clofibrate and inactive ingredients including color, and gelatin as described in the 1988 PDR. The squalene synthetase inhibitor and clofibrate may be employed in separate dosage forms or combined in a single capsule form to lower elevated serum cholesterol or treat atherosclerosis in accordance with the present invention.
Z~7~
Examples 4 to 6 Sgualene synthetase inhibitor tablets described in Examples 1, 2 and 3, respectively, may be employed in combination with cholestyramine resin containing 4 g cholestyramine, acacia, citric acid, color, flavor, polysorbate 80, propylene glycol alginate and sucrose as described in the 1988 PDR. The squalene synthetase inhibitor and cholestyramine may be employed in separate dosage forms or combined in a single capsule form to lower serum cholesterol or treat atherosclerosis in accordance with the present invention..
Exam~les 7 to 10 Squalene synthetase inhibitor tablets, prepared as described in Examples l, 2 and 3, respectively, may be employed in combination with nicotinic acid, colestipol, dextrothyroxine or other serum cholesterol lowering agent in accordance with the teaching of the present invention to lower cholesterol or treat atherosclerosis.
It will also be appreciated that any of the sgualene synthetase inhibitors disclosed in the Biller et al. paper and in pending U.S. patent application Serial No. 141,744 may be employed in combination with any of the serum cholesterol lowering agents disclosed herein in accordance wi~h the present invention.
Claims (16)
1. A pharmaceutical combination comprising an inhibitor of the enzyme squalene synthetase and a pharmaceutical which reduces serum cholesterol and/or inhibits cholesterol biosynthesis by a mechanism other than inhibiting production of the enzyme HMG CoA reductase or squalene synthetase.
2. The combination as defined in Claim 1 wherein said pharmaceutical is an antihyperlipoproteinemic agent or antihyperlipemic agent.
3. The combination as defined in Claim 2 wherein said antihyperlipoproteinemic agent or antihyperlipemic agent is probucol, gemfibrozil, clofibrate, dextrothyroxine or its sodium salt, colestipol or its hydrochloride, cholestyramine, nicotinic acid, neomycin, p-aminosalicylic acid or aspirin.
4. The combination as defined in Claim 1 wherein said pharmaceutical is a bile acid sequestrant.
5. The combination as defined in Claim 4 wherein said bile acid sequestrant is cholestyramine, colestipol, DEAE-Sephadex, a poly(diallylmethylamine) derivative, an ionene or the quaternary amine poly(diallyldimethylammonium) chloride.
6. The combination as defined in Claim 1 wherein said inhibitor of the enzyme squalene synthetase has the formula or wherein R1 is or
7. The combination as defined in CLaim 1 wherein the inhibitor of the enzyme squalene synthetase is present in a weight ratio to said pharmaceutical of within the range of from about 0.001:1 to about 1000:1.
8. The combination as defined in Claim 6 wherein said pharmaceutical is probucol, gemfibrozil, nicotinic acid, cholestyramine, clofibrate, colestipol or p-aminosalicyclic acid.
9. The combination as defined in Claim 6 wherein said pharmaceutical is probucol or gemfibrozil.
10. A method for lowering serum cholesterol or inhibiting formation of or treating atherosclerosis, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical combination comprising an inhibitor of the enzyme squalene synthetase and a pharmaceutical which reduces serum cholesterol by a mechanism other than inhibiting production of the enzymes squalene synthetase and HMG CoA
reductase.
reductase.
11. The method as defined in Claim 10 wherein said pharmaceutical is an antihyperlipoproteinemic agent or antihyperlipemic agent.
12. The method as defined in Claim 11 wherein said antihyperlipoproteinemic agent or antihyperlipemic agent is probucol, gemfibrozil, clofibrate, dextrothyroxine or its sodium salt, colestipol or its hydrochloride, cholestyramine, nicotinic acid, neomycin, p-aminosalicylic acid or aspirin.
13. The method as defined in Claim 10 wherein said pharmaceutical is a bile acid sequestrant.
14. The method as defined in Claim 13 wherein said bile acid sequestrant is cholestyramine, colestipol, DEAE-Sephadex, a poly(diallylmethylamine) derivative, an ionene or the quaternary amine poly(diallyldimethylammonium) chloride.
15. The method as defined in Claim 10 wherein said pharmaceutical is probucol, gemfibrozil, nicotinic acid, cholestyramine, clofibrate, colestipol or p-aminosalicyclic acid.
16. A hypocholesterolemic or hypolipemic composition comprising a combination as defined in Claim 1 and a pharmaceutically acceptable carrier therefor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30453489A | 1989-02-01 | 1989-02-01 | |
US304,534 | 1989-02-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2007641A1 true CA2007641A1 (en) | 1990-08-01 |
Family
ID=23176935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002007641A Abandoned CA2007641A1 (en) | 1989-02-01 | 1990-01-12 | Combination of squalene synthetase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination |
Country Status (6)
Country | Link |
---|---|
JP (1) | JPH02235820A (en) |
CA (1) | CA2007641A1 (en) |
DE (1) | DE4002825C2 (en) |
FR (1) | FR2642310B1 (en) |
GB (1) | GB2227663B (en) |
IT (1) | IT1238079B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6264938B1 (en) | 1997-11-05 | 2001-07-24 | Geltex Pharmaceuticals, Inc. | Combination therapy for treating hypercholestrolemia |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993013801A1 (en) * | 1992-01-17 | 1993-07-22 | The Procter & Gamble Company | Treatment for atherosclerosis |
US6203785B1 (en) | 1996-12-30 | 2001-03-20 | Geltex Pharmaceuticals, Inc. | Poly(diallylamine)-based bile acid sequestrants |
DE10038043B4 (en) * | 2000-08-02 | 2006-09-07 | Walter, Michael, Dr. | Phamacologically active substance for the treatment of cardiovascular diseases |
AU2003218270A1 (en) | 2002-03-19 | 2003-10-08 | Genzyme Corporation | Phosphate transport inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5612114B2 (en) * | 1974-06-07 | 1981-03-18 | ||
US4871721A (en) * | 1988-01-11 | 1989-10-03 | E. R. Squibb & Sons, Inc. | Phosphorus-containing squalene synthetase inhibitors |
CA2003478A1 (en) * | 1988-12-12 | 1990-06-12 | Leonard G. Dennick | Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination |
-
1990
- 1990-01-12 CA CA002007641A patent/CA2007641A1/en not_active Abandoned
- 1990-01-30 GB GB9002018A patent/GB2227663B/en not_active Expired - Fee Related
- 1990-01-31 FR FR909001123A patent/FR2642310B1/en not_active Expired - Fee Related
- 1990-01-31 DE DE4002825A patent/DE4002825C2/en not_active Expired - Fee Related
- 1990-02-01 IT IT01921990A patent/IT1238079B/en active IP Right Grant
- 1990-02-01 JP JP2023627A patent/JPH02235820A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6264938B1 (en) | 1997-11-05 | 2001-07-24 | Geltex Pharmaceuticals, Inc. | Combination therapy for treating hypercholestrolemia |
US6365186B1 (en) | 1997-11-05 | 2002-04-02 | Geltex Pharmaceuticals, Inc. | Combination therapy for treating hypercholesterolemia |
US7638524B2 (en) | 1997-11-05 | 2009-12-29 | Genzyme Corporation | Combination therapy for treating hypercholesterolemia |
Also Published As
Publication number | Publication date |
---|---|
GB2227663A (en) | 1990-08-08 |
IT9019219A0 (en) | 1990-02-01 |
IT9019219A1 (en) | 1990-08-02 |
FR2642310A1 (en) | 1990-08-03 |
GB9002018D0 (en) | 1990-03-28 |
IT1238079B (en) | 1993-07-05 |
FR2642310B1 (en) | 1991-10-25 |
DE4002825A1 (en) | 1990-08-02 |
DE4002825C2 (en) | 1998-08-27 |
GB2227663B (en) | 1993-03-17 |
JPH02235820A (en) | 1990-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2016467A1 (en) | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor | |
US5593971A (en) | Method for preventing onset of hypertension employing a cholesterol lowering drug | |
Kita et al. | Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase | |
US5883109A (en) | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug | |
US5260305A (en) | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination | |
KR100200467B1 (en) | Pharmaceutical composition stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | |
CA2007643A1 (en) | Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination | |
EP0383432B1 (en) | Coenzyme q10 with hmg-coa reductase inhibitors | |
CA2039763A1 (en) | Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination | |
CA2007641A1 (en) | Combination of squalene synthetase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination | |
CA2003478A1 (en) | Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination | |
US5470877A (en) | Uses of perillic acid methyl ester | |
CA2017692C (en) | Carboxamide derivatives | |
AU604176B2 (en) | Dl-5-{2-benzyl-3,4-dihydro-2h-benzopyran-6-yl}methyl} thiazolidine-2,4-dione as an anti-atherosclerosis agent | |
EP1024804A1 (en) | Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels | |
US5686494A (en) | Pharmaceutical preparations for ameliorating epigastric functional disorders | |
Tanaka et al. | Calcium-independent activation of calcium ion dependent cyclic nucleotide phosphodiesterase by synthetic compounds: quinazolinesulfonamide derivatives | |
Harwood Jr et al. | Efficacy, tissue distribution and biliary excretion of methyl (3R∗, 5S∗)-(E)-3, 5-dihydroxy-9, 9-diphenyl-6, 8-nonadienoate (CP-83101), A hepatoselective inhibitor of HMG-CoA reductase activity in the rat | |
US6630502B2 (en) | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | |
US3928602A (en) | Substituted phenoxymalonic acids, esters thereof and hypolipaemic agents containing the same for lowering lipid levels | |
HU193238B (en) | Process for preparing indanyl-derivatives and pharmaceutical compositions containing such compounds | |
WO1998031225A1 (en) | A method of inhibiting or treating phytosterolemia with an mtp inhibitor | |
US3821409A (en) | Method of treatment | |
IL37889A (en) | Compositions for inhibiting indoleamine-n-methyl transferase | |
Parvin et al. | A novel pharmacokinetic approach to determine the relative efficiency of conversion of B-carotene to vitamin A in rats and children |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20000623 |